New AI tool could spot dangerous liver cancer invasion without a biopsy
NCT ID NCT07170345
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing an artificial intelligence system that analyzes CT scans to predict microvascular invasion (MVI) in liver cancer patients. MVI is a key sign of aggressive cancer that currently can only be confirmed after surgery. The AI tool aims to give doctors this information beforehand, helping them plan better surgeries and treatments. The trial will enroll 400 adults with liver cancer who are scheduled for surgery, comparing the AI's predictions to standard lab results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Artificial intelligence-based computer-aided diagnosis (CAD) system
- What this could lead to
- If successful, this could provide doctors with a reliable, non-invasive tool to predict microvascular invasion before surgery, helping tailor treatment and potentially improve survival for liver cancer patients.
- What could go wrong
- This is an early-stage observational study, and the AI system may not perform accurately across different hospitals or patient groups. It is not yet proven to improve patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgeng Hospital
RECRUITINGBeijing, China
-
Beijing YouAn Hospital
RECRUITINGBeijing, China
-
Dazhou Central Hospital
RECRUITINGDazhou, Sichuan, China
-
Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, China
-
Fifth Affiliated Hospital, Sun Yat-Sen University
RECRUITINGZhuhai, Guangdong, China
-
First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
-
First Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, China
-
First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
-
Guangdong Provincial Hospital of Traditional Chinese Medicine
RECRUITINGGuangzhou, Guangdong, China
-
Guizhou Provincial People's Hospital
RECRUITINGGuiyang, Guizhou, China
-
Henan Provincial People's Hospital
RECRUITINGZhengzhou, Henan, China
-
Meng Chao Hepatobiliary Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China
-
Shengjing Hospital
RECRUITINGShenyang, Liaoning, China
-
The First People's Hospital of Yunnan Province
RECRUITINGKunming, Yunnan, China
-
West China Hospital
RECRUITINGChengdu, Sichuan, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, China
-
Zhuhai People's Hospital
RECRUITINGZhuhai, Guangdong, China
-
Zhujiang Hospital
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?